• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Novel prophylactic anticoagulation scoring tool helps stratify patients following lower limb trauma

byNeel MistryandTeddy Guo
April 11, 2024
in Chronic Disease, Hematology, Orthopedic Surgery
Reading Time: 2 mins read
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Share on FacebookShare on TwitterShare on LinkedIn

1. The 3-month symptomatic venous thromboembolism rate was 0.7% in patients with TRiP(cast) score < 7 and not receiving anticoagulation.

2. There was no significant difference between the control and intervention phases regarding secondary outcomes.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Venous thromboembolism (VTE) is a well-recognized potential complication resulting from orthopedic trauma and periods of prolonged immobilization. However, there exists a lack of consensus around prophylactic anticoagulation among patients with lower limb trauma requiring immobilization. This randomized controlled trial aimed to assess the safety of withholding anticoagulation for lower-risk patients with lower limb trauma based on the Thrombosis Risk Prediction for Patients with Cast Immobilization – TRiP(cast) scores. The primary outcome was the cumulative rate of VTE at three months, while key secondary outcomes were the incidence of major and non-major bleeding. According to study results, patients with TRiP(cast) score <7 reported a less than one percent risk of developing VTE which was lower than the prespecified cutoffs. Although this study was well done, it was limited by its focus on specific regions and settings, thus affecting the generalizability of results.

Click to read the study in The Lancet

Relevant Reading: Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture

RELATED REPORTS

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

In-depth [randomized-controlled trial]: Between Jun 16, 2020, and Sept 15, 2021, 25 clusters were assessed for eligibility across 15 emergency departments (EDs) in France and Belgium. Included were patients ≥ 18 years old who presented to ED with lower limb trauma requiring immobilization for ≥ 7 days. Altogether, 2120 patients were included in the final analysis, with 1505 in the intervention phase. The primary outcome concerning the 3-month cumulative rate of symptomatic VTE in patients with a TRiP(cast) score < 7 was 0.7% (95% confidence interval [CI] 0.3–1.4). In contrast, the 3-month rate of VTE in patients with a TRiP(cast) score ≥ 7 was 2.7% (95% CI 1.2–4.9) despite the use of anticoagulation. The secondary outcome, including bleeding rates, showed no significant difference between the control and intervention phases. Findings from this study suggest that withholding anticoagulation for lower-risk patients may be safe and reduce the need for thromboprophylaxis in patients following lower limb trauma.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #oral anticoagulationanticoagulationlower limb injurylower limb traumaprophylactic anticoagulationTRiP(cast) scorevenous thromboembolismvenous thromboembolism (VTE)
Previous Post

#VisualAbstract: Pazopanib does not improve disease-free survival post-metastasectomy for renal cell carcinoma patients

Next Post

#VisualAbstract: Imetelstat improves blood transfusion independence in lower-risk myelodysplastic syndromes

RelatedReports

Drug comparison trials collage: a brass balance scale with white tablets on one pan and gray capsules on the other
Cardiology

Apixaban (eliquis) outperforms Rivaroxaban (xarelto) in venous thromboembolism bleeding risk

April 9, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Blood clots collage: a cutaway vein where a fibrin mesh unravels among red blood cells, an engraved eye and a pill bottle
Pharma

Apixaban reduces bleeding risk versus rivaroxaban in acute venous thromboembolism

March 23, 2026
Atrial fibrillation collage: an engraved heart with teal upper chambers, paper sparks and a dotted teal ribbon around it
Cardiology

Left atrial appendage closure is safe and effective in atrial fibrillation

January 13, 2026
Next Post
#VisualAbstract: Imetelstat improves blood transfusion independence in lower-risk myelodysplastic syndromes

#VisualAbstract: Imetelstat improves blood transfusion independence in lower-risk myelodysplastic syndromes

Intracytoplasmic sperm injection offers no benefit over in-vitro fertilization for non-severe male factor infertility

2 Minute Medicine Rewind April 15, 2024

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • AI health chatbot shows no benefit for perinatal anxiety or depression
  • ADCE-D01 showed a 30% objective response rate in topline phase 1 results for previously treated advanced soft tissue sarcoma
  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.